ReviewBone marrow transplantation2025
Regulatory T cell therapy for Graft-versus-Host Disease.
Review in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Orca-T: First Approval.Molecular diagnosis & therapy · 2026Article
- A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease.Dermatology and therapy · 2026Review
- Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.Molecular therapy. Advances · 2026Article
- Cell Therapy and Graft Engineering for Chronic Graft-versus-host Disease.Stem cell reviews and reports · 2026Review
- Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives.Clinical and experimental medicine · 2026Review
- Higher HLA-DRB1 Evolutionary Divergence Is Associated with Reduced Relapse and Improved Survival after Matched Unrelated Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2026Article
- Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Graft-versus-Host Disease (GvHD) is the main cause of morbidity and mortality of allogeneic hematopoietic cell transplantation (allo-HCT). Conventional immunosuppressive pharmacotherapy remains the backbone of GvHD prevention and treatment with suboptimal outcomes especially for patients with refractory disease. Adoptive immunotherapy with regulatory T-cells (Treg) stands as an alternative approach that aims to restore immune tolerance and circumvent prolonged immunosuppression albeit preserving the beneficial Graft-versus-Leukaemia (GvL) effect. In this review, we summarise recent knowledge on Treg biology, clinical applications of various Tregs subtypes in the setting of GvHD and future endeavours of the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.